Sublingual administration of vitamin b12 dispersed in a hydrophobic continuous phase

Abstract

Vitamin B12 for use in the treatment of a condition in a subject is administered sublingually. The vitamin B12 is dispersed in a hydrophobic continuous phase, such as oil or fat. The condition to be treated is vitamin B12 deficiency.

1 . A method treatment of a condition in a subject, comprising:
 administering vitamin B12 sublingually, wherein the vitamin B12 is dispersed in a hydrophobic continuous phase.   
     
     
         2 . The method according to  claim 1 , wherein the hydrophobic continuous phase is chosen from at least one of i) fat, ii) fatty acids, and iii) wax. 
     
     
         3 . The method according to  claim 1 , wherein the hydrophobic continuous phase is oil. 
     
     
         4 . The method according to  claim 1 , wherein the hydrophobic continuous phase is anhydrous. 
     
     
         5 . The method according to  claim 1 , wherein the vitamin B12 is chosen from at least one of cyano-cobalamin, hydroxo-cobalamin, methyl-cobalamin, 5′-deoxyadenosyl-cobalamin, aquacobalamin, glutathionyl-cobalamin and nitrilocobalamin. 
     
     
         6 . The method according to  claim 1 , wherein the concentration of vitamin B12 in the hydrophobic continuous phase is in the range of 0.05 wt. % to 10 wt. % 
     
     
         7 . The method according to  claim 1 , wherein vitamin B12 is colloidally dispersed in the hydrophobic continuous phase. 
     
     
         8 . The method according to  claim 1 , wherein the subject is a human subject or an animal subject. 
     
     
         9 . The method according to  claim 1 , wherein the condition is chosen from vitamin B12 deficiency, autism spectrum disorder, fatigue, memory deficiency, ALS, Alzheimer, deficiency caused by drug abuse, thinning of the stomach lining, vitamin B12 deficiency after surgery in which part of the stomach and/or small intestine is removed, Crohn's disease, celiac disease, Graves' disease, systemic lupus erythematosus and migraine. 
     
     
         10 . The method according to  claim 1 , wherein the concentration of vitamin B12 in the hydrophobic continuous phase is between 0.4 wt. % and 8 wt. %.